ClinicalTrials.gg
TerminatedNCT01461005DSSUpdated Feb 19, 2020Results posted

A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System (DSS)

An interventional study of Dynamic Stabilization System (DSS) in Spondylolisthesis, Neurologic Deficits and Kyphosis, sponsored by Paradigm Spine. Terminated at 1 site in United States. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-02-19.

Sponsored by Paradigm Spine · Not applicable, Interventional, and Treatment

Why this study was terminated
FDA reclassified so all 522 studies were stopped,
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
21 Years to 85 Years
Sex
All
01

Study summary

The purpose of the Post-Market Surveillance study is to evaluate safety.

Read the detailed description

Paradigm Spine Dynamic Stabilization System (DSS) study is a prospective, multi-center, literature controlled study.

02

Conditions studied

  • Spondylolisthesis
  • Neurologic Deficits
  • Kyphosis
  • Pseudarthrosis

Keywords

  • Spondylolisthesis
  • Neurologic impairment
  • Kyphosis
  • Pseudarthrosis
03

In context

Spondylolisthesis

227 studies on the registry are indexed under Spondylolisthesis; 43 are open to participants now.

This study's enrollment of 1 is below the median of 60 across 143 interventional studies indexed under Spondylolisthesis.

Browse Spondylolisthesis studies →

Lead sponsor

Paradigm Spine is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is skeletally mature (21-85 years old).
  • Patient has degenerative spondylolisthesis (Grade 1-3) with objective evidence of neurologic impairment, kyphosis, and/or failed previous fusion (pseudarthrosis) at index level.
  • Capable and willing to comply with the requirements unique to the study, adhere to the post-operative treatment and management program, and return for required follow-up examinations.
  • Surgeon has determined that DSS™ System is an appropriate treatment for the patient without regard to the study.

Exclusion criteria

Exclusion Criteria:

  • The need for interbody cages, allograft, or any other assistance during surgery. Device is only to be used with autograft per FDA approved indications.
  • Any medical, mental or surgical condition precluding the potential benefit of spinal surgery or surgery in general.
  • Acute or chronic systemic, spinal or localized infections.
  • Active, severe systemic and metabolic diseases.
  • Obesity defined as > 35.
  • Subject is pregnant or interested in becoming pregnant in the next 36 months.
  • Dependency on pharmaceutical drugs, drug abuse, or alcoholism.
  • Lack of patient cooperation.
  • Foreign body sensitivity to the implant material.
  • Degenerative scoliosis greater than 25 degrees.
  • Grade 4 degenerative spondylolisthesis (>75% slip).
  • Significant osteopenia A screening questionnaire for osteopenia, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA bone mineral density measurement. If DEXA is required*, exclusion will be defined as a DEXA bone density measured T score of ≤ -1.0 (The World Health Organization definition of osteopenia).
  • Soft tissue deficit not allowing wound closure.
  • Congenital abnormalities, tumors or other conditions that would prevent secure component fixation that has the potential to decrease the useful life of the device.
  • Inadequate pedicles or vertebral body geometry of the thoracic, lumbar and sacral vertebrae.
  • Bony lumbar spinal stenosis not related to the primary degenerative spondylolisthesis indication.
  • Pars defect.
  • Clinically compromised vertebral bodies at affected level due to current or past trauma.
  • Prisoner or ward of the state.
  • Currently in litigation regarding a spinal condition.
  • Known allergy to titanium, titanium alloys, CoCrMo, polyethylene or MR contrast agents.
  • Is currently involved in a study of another product for similar purpose.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Dynamic Stabilization System

    Dynamic Stabilization System (DSS) System

    Device: Dynamic Stabilization System (DSS)

Interventions

  • DeviceDynamic Stabilization System (DSS)

    Dynamic Stabilization System

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure.

    The safety endpoint is defined as the incidence of serious or device related adverse events attributable to the device or procedure. Reoperations, revisions or removals of the Dynamic Stabilization System (DSS) System implant will be evaluated.

    Time frame: 6 months

Secondary outcomes

  1. Measurement of Lower Back Pain as Assessed by Visual Analog Scale

    Lower back pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)

    Time frame: 6 months

  2. Measurement of Right Leg Pain as Assessed by Visual Analog Scale

    Right leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)

    Time frame: 6 months

  3. Measurement of Left Leg Pain as Assessed by Visual Analog Scale

    Left leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)

    Time frame: 6 months

  4. Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline.

    The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 "worst imaginable health state" to 100 "best imaginable health state".

    Time frame: Pre-Op, 6 weeks, 6 months, 12 months, and 24 months

  5. Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI).

    ODI is a questionnaire that provides information on back and the affects on managing every day life by diving questions into 10 sections. The total possible score for each section is 0-5. The scores are then converted into percentages ranging from 0% (minimal disability) to 100% (maximum possible disability).

    Time frame: 6 months

07

Results

Posted Oct 15, 2019

Participant flow

Participant flow — Overall Study
MilestoneDynamic Stabilization System
Started1
Completed0
Not completed1
Withdrew: Fda reclassified dynamic stabilization d1

Outcome measures

PrimaryNumber of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure.

The safety endpoint is defined as the incidence of serious or device related adverse events attributable to the device or procedure. Reoperations, revisions or removals of the Dynamic Stabilization System (DSS) System implant will be evaluated.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure.
ParticipantsDynamic Stabilization System
Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure.0
SecondaryMeasurement of Lower Back Pain as Assessed by Visual Analog Scale

Lower back pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)

Time frame:
6 months
Reported as:
Number · units on a scale
Measurement of Lower Back Pain as Assessed by Visual Analog Scale
units on a scaleDynamic Stabilization System
Measurement of Lower Back Pain as Assessed by Visual Analog Scale2
SecondaryMeasurement of Right Leg Pain as Assessed by Visual Analog Scale

Right leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)

Time frame:
6 months
Reported as:
Number · units on a scale
Measurement of Right Leg Pain as Assessed by Visual Analog Scale
units on a scaleDSS Stabilization System
Measurement of Right Leg Pain as Assessed by Visual Analog Scale2
SecondaryMeasurement of Left Leg Pain as Assessed by Visual Analog Scale

Left leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)

Time frame:
6 months
Reported as:
Number · units on a scale
Measurement of Left Leg Pain as Assessed by Visual Analog Scale
units on a scaleDSS Stabilization System
Measurement of Left Leg Pain as Assessed by Visual Analog Scale12
SecondaryNumber of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline.

The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 "worst imaginable health state" to 100 "best imaginable health state".

Time frame:
Pre-Op, 6 weeks, 6 months, 12 months, and 24 months
Reported as:
Number · participants
Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline.
participantsDSS Stabilization System
Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline.1
SecondaryAssessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI).

ODI is a questionnaire that provides information on back and the affects on managing every day life by diving questions into 10 sections. The total possible score for each section is 0-5. The scores are then converted into percentages ranging from 0% (minimal disability) to 100% (maximum possible disability).

Time frame:
6 months
Reported as:
Number · score on a scale
Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI).
score on a scaleDSS Stabilization System
Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI).2

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dynamic Stabilization System—0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)DSS Stabilization System
Mean67 ± 0
Sex: Female, Male
Sex: Female, Male(Participants)DSS Stabilization System
Female1
Male0
Region of Enrollment
Region of Enrollment(Participants)DSS Stabilization System
United States1
08

Study locations

1 site
  • University of California, Davis Medical Center
    Sacramento, California 95816, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01461005
Lead sponsor
Paradigm Spine
Collaborators
MCRA
Responsible party
Sponsor
First posted
Oct 27, 2011
Start date
Sep 2011
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Oct 15, 2019
Last update
Feb 19, 2020

Study contacts

Gitela Gandelman
study director · Paradigm Spine LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion